HALB
Halberd Corporation0.0013
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
826.64KP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
Financial restatement announced
Halberd Corporation disclosed on September 14, 2022, that its auditor BF BORGERS requires restating financial statements in its Form 10-Q for April 30, 2022, and Form 10-12G for years ended July 31, 2021 and 2020, to correct errors in presenting convertible judgments payable and accounts payable under ASC 250. The adjustments will alter the balance sheet, net income, and EPS but leave cash position, operations, and liquidity untouched. A material weakness in internal controls over contingencies triggered this. Remediation is underway.
10-Q
Q3 FY2022 results
Halberd Corporation posted modest revenue growth to $1,217 in Q3 FY2022 ended April 30, 2022, up 6% y/y from $1,144, while nine-month revenue climbed 41% y/y to $5,883, driven by CBD product sales with costs now minimal after prior impairments. Yet operating losses widened to $295,634 in the quarter (up 30% y/y) and $1,360K YTD (up 128% y/y), fueled by $710K in R&D outsourcing to Arizona State University and $576K in professional fees, mostly non-cash warrants for services. Cash dwindled to $8K amid $773K operating outflow, offset by $745K contributed capital; the $150K SBA loan at 3.75% remains outstanding with payments deferred to 2022. EPS holds at $(0.00) with no dilution from 513M shares. Warrants fuel innovation. Regulatory hurdles in clinical trials loom large.
8-K
Presentation disclosed in 8-K
8-K
CFO resigns; interim appointed
Halberd Corporation announced the immediate resignation of interim CFO Joel M. Ungar on June 23, 2009, with no disagreements cited. John Maddox, the company's 43-year-old President and COO since inception, stepped in as interim CFO that day. Maddox brings over 16 years of CPA experience from firms like Grant Thornton. Leadership transition ensures continuity amid the board's search.
8-K
Interim CFO resigns abruptly
Halberd Corporation's interim CFO Joel M. Ungar resigned effective June 23, 2009, to resume full-time duties at his accounting firm, with no disagreements noted. John Maddox, the company's President and COO since inception, steps in as interim CFO amid the board's search for a permanent replacement. Maddox brings over 16 years of CPA experience. This leadership shift supports the firm's recent public transition.
IPO
Sector
Industry
ALZN
Alzamend Neuro, Inc.
2.16+0.05
CRVO
CervoMed Inc.
8.35+0.00
CYBN
Cybin Inc.
6.66+0.00
FBLG
FibroBiologics, Inc.
0.24-0.02
HSDT
Solana Company
3.10+0.06
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
KTTA
Pasithea Therapeutics Corp.
1.14-0.02
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
PASG
Passage Bio, Inc.
9.45-0.60
YDES
YD Bio Limited
12.62+0.22